Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation

Furthermore, we could selectively degrade BRD4 protein in tumor tissue enabled by tumor-targeted tetrazine compound IR808-TZ. This strategy may represent an alternative to existing strategies and may be widely applied in the design of BT-PROTAC targeting other proteins.